Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

CVS Health raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health ...

CVS Caremark, OptumRx, Express Scripts and other PBMs remained loyal to big-ticket brand-name pharmaceuticals such as Humira, in part because they enjoyed lucrative rebates from drugmakers.

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...

Shares of CVS Health jumped after the company reported a strong first quarter and agreed to open up access to Novo Nordisk's weight-loss medication at more affordable prices. The stock was up 8.7% at ...

CVS also tapped Ed DeVaney to serve as permanent president of CVS Caremark, the healthcare giant’s pharmacy benefit manager, in February. Joyner had previously led the PBM.

CVS Caremark added five new companies to its Point Solution Management Service, which it launched last year to make it easier for businesses to implement digital health tools. CVS Caremark CMO ...

responsible for the operational performance across CVS Caremark, CVS Pharmacy, and the company's Healthcare Delivery businesses.